Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-01-05
Target enrollment:
Participant gender:
Summary
Lung cancer is the leading cause of cancer death in the country, surpassing deaths caused by
colorectal, prostate and breast cancers combined. Veterans are at higher risk of lung cancer
due to the higher rate of smoking and environmental toxin exposures. The lack of effective
therapy for lung cancer provides the impetus to search for alternative, safe, and effective
treatment agents to improve treatment strategy against lung cancer, enhance the probability
of a cure and reduce recurrence. Based on encouraging preclinical and clinical findings from
an early phase I lung cancer prevention study, using a special formulation of a standardized
grape seed extract with enhanced absorption called leucoselect phytosome (LP), the purpose of
this new CSR&D Merit Review project is to evaluate the potential usefulness of LP for
pre-surgical treatment of early stage lung cancer patients in a phase IIa clinical trial.
Findings from this study may set the stage for larger, confirmatory trials in the near
future.